A Novel Platelet-Activating Factor Receptor Antagonist Inhibits Choroidal Neovascularization and Subretinal Fibrosis

Han Zhang1,2*, Yang Yang1, Atsunobu Takeda1, Takeru Yoshimura1, Yuji Oshima1, Koh-Hei Sonoda3, Tatsuro Ishibashi1

1 Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, 2 Department of Ophthalmology, the First Hospital of China Medical University, Shenyang, China, 3 Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan

Abstract

Choroidal neovascularization (CNV) is a critical pathogenesis in age-related macular degeneration (AMD), the most common cause of blindness in developed countries. To date, the precise molecular and cellular mechanisms underlying CNV have not been elucidated. Platelet-activating factor (PAF) has been previously implicated in angiogenesis; however, the roles of PAF and its receptor (PAF-R) in CNV have not been addressed. The present study reveals several important findings concerning the relationship of the PAF-R signaling with CNV. PAF-R was detected in a mouse model of laser-induced CNV and was upregulated during CNV development. Experimental CNV was suppressed by administering WEB2086, a novel PAF-R antagonist. WEB2086-dependent suppression of CNV occurred via the inhibition of macrophage infiltration and the expression of proangiogenic (vascular endothelial growth factor) and proinflammatory molecules (monocyte chemotactic protein-1 and IL-6) in the retinal pigment epithelium–choroid complex. Additionally, WEB2086-induced PAF-R blockage suppresses experimentally induced subretinal fibrosis, which resembles the fibrotic subretinal scarring observed in neovascular AMD. As optimal treatment modalities for neovascular AMD would target the multiple mechanisms of AMD-associated vision loss, including neovascularization, inflammation and fibrosis, our results suggest PAF-R as an attractive molecular target in the treatment of AMD.

Introduction

Neovascular age-related macular degeneration (AMD) leads to severe deterioration of central vision in elderly individuals owing to the development of choroidal neovascularization (CNV) in the macular region [1]. Abnormal new blood vessels initially proliferate under Bruch’s membrane and the retinal pigment epithelium (RPE) and then invade the subretinal space, leading to subretinal hemorrhages, exudative lesions, serous retinal detachment, and ultimately disciform scarring [2]. Local destruction of photoreceptors, RPE, and choroidal blood vessels leads to irreversible loss of macular function and vision.

CNV is regarded as a submacular wound healing process that requires a continually evolving interaction among cells, cytokines, and the extracellular matrix [2,3]. Angiogenesis is an essential component of this process, and current clinical strategies for treating CNV are primarily aimed at inhibiting vascular endothelial growth factor (VEGF), the major promoter of angiogenesis [4,5]. However, overall only 30%–40% of exudative AMD patients gain three lines in visual acuity, and approximately 1 in 6 patients experience progressive loss in visual acuity that leads to legal blindness despite standard treatment with potent VEGF inhibitors [6–8]. These results are not surprising because angiogenesis is only one component of the wound healing process and because CNV pathogenesis extends beyond the endothelium. Therefore, CNV may be amenable to additional therapeutic alternatives besides anti-angiogenesis. During the past decade, several studies have examined the immune mechanisms in AMD and have reached the consensus that inflammation is a key driver in the development of neovascular AMD [2,3,9–11]. AMD is regarded as the result of an ongoing low-grade chronic inflammatory process, much like Alzheimer’s disease and other chronic diseases of aging. This inflammatory process includes macrophage infiltration and the regulation of cytokine networks, which mediate CNV development [9].

Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine), the first bioactive lipid ever identified, is a potent proinflammatory mediator that is involved in cellular activation, intracellular signaling, apoptosis, and diverse inflammatory reactions [12–15]. Its biological actions are mediated through the activation of a G protein-coupled PAF receptor (PAF-R) [16]. Several studies have suggested the involvement of PAF in angiogenesis. PAF directly stimulates the in vitro migration of endothelial cells, enhances vascular permeability, and promotes in vivo angiogenesis [17–21]. The results of animal studies suggest that PAF may contribute to the angiogenic activity of certain
cytokines by stimulating the production of VEGF, tumor necrosis factor-alpha, and hepatocyte growth factor [19,22,23]. A recent study shows that PAF-R is present in RPE cells and choroidal endothelial cells, and PAF upregulates VEGF in RPE cells [24]. Because these cell types are important for CNV development, these findings suggest that PAF may be involved in the pathogenesis of neovascular AMD. However, in vivo evidence supporting the role of PAF and PAF-R in CNV has not been reported.

In the present study, we demonstrate that local expression of PAF-R in the subretinal space is upregulated during CNV development. Administration of the PAF-R antagonist potentially attenuated CNV lesion size by suppressing macrophage infiltration and the expression of multiple CNV-related molecules in the injured eye. We further report that PAF-R blockade inhibits experimental subretinal fibrosis. Thus, PAF-R blockade may provide a novel, effective treatment for neovascular AMD.

Materials and Methods

Animals

Female 7- to 10-week-old C57BL/6 mice were purchased from Japan SLC (Shizuoka, Japan) and used in all experiments. All animal experiments were approved by the Committee on the Ethics of Animal Experiments, Graduate School of Medical Sciences, Kyushu University, Japan. Animals were treated according to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

Induction and Evaluation of CNV

CNV was induced by photocoagulation as described previously, with some modifications [25]. In brief, laser photocoagulation was applied around the optic disc using a 532-nm diode laser (200 mW, 0.1-s duration, 75-μm diameter; Iridex, Mountain View, CA) to burn the posterior pole of the retina (4 spots/eye). Only lesions in which a subretinal bubble developed were used in subsequent experiments. Ten days after photocoagulation, the mice were anesthetized and perfused with 50 mg/ml of fluorescein-labeled dextran (2×10^6 average molecular weight; Sigma, St. Louis, MO). Following enucleation and fixation in 4% paraformaldehyde, corneas and lenses were removed, and each entire retina was dissected from the eye cup. After each eye cup was flat-mounted, the total area of hyperfluorescence associated with each burn was measured using ImageJ software (National Institutes of Health, Bethesda, MD).

Treatment with PAF-R Antagonist

Animals were treated with the PAF-R antagonist WEB2086 (Santa Cruz Biotechnology, Santa Cruz, CA) or phosphate-buffered saline (PBS, used as vehicle) 1 h before photocoagulation, and treatments were continued daily until the end of the study. WEB2086 was administered intraperitoneally to mice at 5 mg/kg body weight.

In some experiments, mice were injected intravitreally with 1 μg WEB2086 in 0.5 μl of PBS immediately after laser photocoagulation using 32-gauge needles (Hamilton, Reno, NV) under an operating microscope. Injections were repeated every other day for the duration of the study.

Immunohistochemistry and Immunofluorescence

For PAF-R staining, cryostat sections (6-μm thick) from naïve and laser-treated eyes (5 days after photocoagulation) were incubated with polyclonal rabbit anti-PAF-R antibody (1:100, Santa Cruz Biotechnology) and bovine anti-rabbit IgG-HRP (Santa Cruz Biotechnology), followed by the chromogen AEC (Vector Laboratories, Burlingame, CA). To bleach the pigment in RPE and choroid, the sections were incubated in 3% H_2O_2 for 18 h at room temperature and then counterstained in hematoxylin.

The FITC-conjugated endothelial cell marker isolecitin B4 (1:200, Vector Laboratories) and the R-PE-conjugated rat antimouse macrophage marker F4/80 (1:100, Invitrogen, Carlsbad, CA) were used for double immunofluorescence staining of choroidal flat mounts (3 days after photocoagulation). The area of F4/80-positive cells within and near the laser lesions was measured using ImageJ and normalized to the size of CNV (100%).

Quantitative Real-time Reverse Transcription Polymerase Chain Reaction (qRT-PCR)

Total RNA was extracted using TRIzol reagent (Invitrogen) from RPE-choroid complexes at various times after CNV induction. Aliquots containing 1 μg of total RNA were reverse transcribed using a first-strand cDNA synthesis kit (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. qRT-PCR was performed using LightCycler (Roche Diagnostics GmbH) and SYBR green real-time PCR mix [Takara Bio, Otsu, Shiga, Japan]. Target sequences were amplified using the following primer pairs: PAF-R, 5′-TTGCCCTGAAGCACCATCCTTATT-3′ and 5′-CCTGCACCTGTTGATTTGCT-3′; VEGF, 5′-GTGCTACTGTGACCCCTGGTGTTAG-3′ and 5′-GTCGTAACCTGTGAAATGTTG-3′; monocyte chemotactic protein (MCP)-1, 5′-AACCTCTCACTGAAGGCAGCT-3′ and 5′-CGTTAACCTGCACTGTGCTGA-3′; IL-6, 5′-TGAGATGCACAGGAGATGTTGCTAAG-3′ and 5′-CTGAGACACAGTTGGAATGTGCCAC-3′; and β-actin, 5′-GATGACCGATATGCATGTTTGA-3′ and 5′-GGAGAGCATAGCCCTCGTAG-3′. All estimated mRNA levels were normalized to β-actin mRNA levels.

Enzyme-linked Immunosorbent Assay (ELISA)

RPE-choroid complexes were isolated at various times following CNV induction and were immersed in 200 μl of tissue protein extraction reagent (T-PER; Pierce, Rockford, IL) supplemented with protease inhibitor cocktail (Halt; Pierce). The mixture was homogenized (Polytron; Kinematica AG) and clarified by centrifuging at 10,000 g for 5 min. VEGF, MCP-1, and IL-6 levels in the lysate were measured using the corresponding mouse VEGF, MCP-1, and IL-6 ELISA kit (R&D Systems, Minneapolis, MN) according to the manufacturer’s protocols.

Induction and Evaluation of Subretinal Fibrosis

Recently, Jo et al. successfully established a mouse model of subretinal fibrosis, resembling the fibrotic subretinal scarring observed in advanced and late-stage neovascular AMD, by introducing inflammatory macrophages into the subretinal space [26]. This model is believed to provoke a significant advance in investigating molecular mechanisms for neovascular AMD and establishing new therapy besides antiangiogenic approaches. In brief, C57BL/6 mice received an intraperitoneal injection of 2.5 ml of thioglycolate, and peritoneal exude cells (PECs) were isolated after 3 days. PECs (4×10^6/ml) then were prepared for subretinal injection. Laser photocoagulation was performed in the posterior pole of each retina, and 0.5 μl of the prepared PECs were injected into each subretinal space using a blunt-tipped needle. Treated eyes that bled or did not exhibit focal retinal detachment
were excluded. WEB2086 (1 μg) or vehicle was injected intravitreally after 2 h, and injections were repeated every other day for the duration of the study. On day 7, the mice were euthanized, and the PEC-injected eyes were removed. After dissecting the cornea and lens from each eye, radial relaxing incisions were made in the eye cups. Staining for glial fibrillary acidic protein (GFAP) was then performed to visualize the area of residual glia on choroidal flat mounts. The GFAP area was measured to quantify subretinal fibrosis because GFAP staining detects and quantitates subretinal fibrosis effectively in this animal model [26]. Polyclonal rabbit anti-GFAP antibody (1:400, Dako, Glostrup, Denmark) and FITC-conjugated anti-rabbit IgG (Invitrogen) were used for GFAP detection. Flat mounts were observed using a fluorescence microscope, and GFAP areas were measured using ImageJ.

Statistical Analysis
Each result is representative of at least three independent experiments. All values represent mean ± SD. Statistical significance was assessed using Student’s t-test (SPSS, Chicago, IL). P<0.05 was considered statistically significant.

Results
PAF-R Expression during Laser-induced CNV Development
PAF-R expression during the development of laser-induced CNV was measured by qRT-PCR (Figure 1A). PAF-R mRNA level was elevated significantly (P<0.01) on day 3 after photocoagulation. By day 5, PAF-R mRNA peaked at levels 6.5-fold higher than the levels at the 0-h baseline (P<0.01). PAF-R expression decreased on day 7, but it remained elevated above the baseline on day 10 (P<0.05). Immunohistochemical staining confirmed the presence of PAF-R in RPE cells and choroidal endothelial cells of naïve samples (Figure 1B), and PAF-R signals became stronger in CNV regions on day 5 after photocoagulation (Figure 1C). Under high magnification, RPE-like cells and endothelial cells in CNV showed PAF-R positivity (data not shown).

Suppression of CNV with WEB2086-induced PAF-R Blockage
CNV areas on flat mounts were measured to evaluate the effects of WEB2086, a PAF-R antagonist, on CNV development. The typical features of experimental CNV in PBS-treated mice 10 days after photocoagulation included broad, flat neovascular nets (Figure 2A and 2C). In contrast, only a few new vessels were observed in mice treated with both intraperitoneal (Figure 2B) and intravitreal (Figure 2D) injections of WEB2086. Quantitative measurement suggested that both systemic and local administration of WEB2086 significantly reduced the CNV area on day 10 (P<0.001 for both, Figure 2E). The neovascular response in mice treated intravitreally was suppressed to a slightly greater, but nonsignificant, extent compared with that in mice treated intraperitoneally. Histological examination indicated no signs of retinal toxicity for intravitreal administration of WEB2086 at this dose (data not shown).

Reduction of Macrophage Infiltration in WEB2086-treated Eyes
We analyzed the infiltration of macrophages into CNV lesions on choroidal flat mounts by immunostaining for F4/80, a macrophage-specific marker. F4/80-positive cells were concentrated within the laser burns and around the edges of the laser scars 72 h after laser injury (Figure 3A). No F4/80-positive cells were observed outside the laser-burned area in the choroid. In comparison, WEB2086 treatment was associated with less infiltration of F4/80-positive cells (Figure 3B). Quantitative measurement of the F4/80-positive area indicated a 57% reduction in F4/80 positivity with WEB2086 treatment (P<0.005, Figure 3C). These data suggest that PAF-R blockage reduces inflammation in CNV lesions.

Inhibition of Proangiogenic and Proinflammatory Molecules with WEB2086
To elucidate the molecular mechanisms involved in the regulation of CNV by WEB2086-induced PAF-R blockage, we measured the mRNA levels of proangiogenic and proinflammatory mediators in RPE–choroid complexes during CNV development. The expression levels of VEGF and the proinflammatory mediators, MCP-1 and IL-6, were significantly elevated and peaked on days 1–3, respectively, following CNV induction in the PBS-treated mice (Figure 4A–C). In the WEB2086-treated mice, the expression levels of VEGF, MCP-1, and IL-6 were significantly reduced by 44%, 52%, and 43%, respectively, at the time of peak expression for each mediator (P<0.01 for all). Similarly, WEB2086-induced PAF-R blockage significantly suppressed the peak protein levels of VEGF, MCP-1, and IL-6 (P<0.01 for all), which were upregulated after CNV induction (Figure 4D–F). These results suggest that these mediators may be targets of the PAF-R signaling pathway during CNV development.

Suppression of Subretinal Fibrosis with WEB2086-induced PAF-R Blockage
Recently, we successfully established a mouse model of subretinal fibrosis that exhibits fibrotic subretinal scarring similar to that observed in advanced and late-stage neovascular AMD by introducing inflammatory macrophages into the subretinal space [26]. This model facilitates investigations of the molecular mechanisms of neovascular AMD and may assist in the establishment of novel therapies that go beyond antiangiogenic approaches. Using this animal model, we evaluated whether WEB2086-induced PAF-R blockage could mitigate subretinal fibrosis. Compared with the PBS-treated mice, the WEB2086-treated mice exhibited a reduced severity of subretinal fibrosis (Figure 5A and 5B). Quantitative measurement of the fibrosis area indicated that PAF-R blockage significantly reduced subretinal fibrosis by 66% (P<0.001, Figure 5C). These observations suggest that PAF-R signaling may be involved in the pathogenesis of subretinal fibrosis.

Discussion
To our knowledge, the present study is the first to characterize the relationship between PAF-R signaling and CNV. We observed PAF-R expression in laser-induced CNV and this expression increased during experimental CNV development. CNV was suppressed by blocking PAF-R using the novel receptor antagonist WEB2086. We report that the cellular and molecular mechanisms of WEB2086-induced CNV suppression included the inhibitory effects on macrophage infiltration and the expression of proangiogenic and proinflammatory molecules in the RPE–choroid complex. We also demonstrated that PAF-R blockage could suppress a model of experimental subretinal fibrosis that resembles the fibrotic subretinal scarring observed in neovascular AMD.

PAF-R has been cloned from several species and contains a seven-transmembrane domain typical of G protein-coupled receptors [16,27]. PAF-R mRNA has been identified in various...
tissues, including spleen, small intestine, kidney, liver, lung, and brain, and in many cell types, including smooth muscle cells, cardiomyocytes, neutrophils, monocytes/macrophages, eosinophils, endothelial cells, and Kupffer cells [28,29]. In the eye, PAF-R localizes to the corneal epithelium, iris/ciliary body, and retina [30–32] and recently was identified in RPE cells and choroidal endothelial cells [24]. Previous studies have indicated that PAF-R was upregulated during inflammatory processes, cancer progression, and wound healing process [33–35]. To our knowledge, the roles of PAF-R in CNV have not been addressed.
previously. We report here that PAF-R is upregulated during laser-induced CNV development. Laser photocoagulation is an established method for generating CNV in animal models. High laser energy causes rupture of Bruch’s membrane, and, under the influence of various angiogenic factors, an ingrowth of choroidal vessels under the RPE and into the subretinal space takes place. Although in this model, pathogenesis of the neovascularization is different from AMD, formation of CNV is believed to follow the same pattern, and identical angiogenetic factors are expressed by the RPE and endothelial cells [36]. Our observations underscore the possibility that PAF-R signaling is important in CNV.

In the present study, both systemic and local blockade of PAF-R using the novel PAF-R antagonist WEB2086 led to significant CNV suppression. Previous studies have revealed that a PAF-R blockade can inhibit endothelial cell migration and vascular permeability [19,37]. In a corneal micropocket assay, the Matrigel model, and in an experimental tumor model, PAF-R antagonists significantly reduced VEGF-related and tumor-related angiogenesis [18,19,38–40]. WEB2086, a thieno-triazolo-diazepine, is a very potent and specific PAF-R antagonist with an affinity for PAF binding sites that is similar to the affinity of PAF itself [41]. Pharmacological data from animal studies support the possibility of using WEB2086 as a peroral, intravenous, or inhaled PAF-R antagonist at low dosage [41]. However, data are lacking regarding the pharmacological properties, toxicology, and safety profiles associated with intraocular administration of WEB2086. Our results demonstrated that intravitreal administration of WEB2086 inhibits laser-induced CNV without retinal destruction.

Figure 3. Suppressive effects of PAF-R blockage on macrophage infiltration in CNV. Immunohistochemical analysis of lesions in the choroid of vehicle- (A) or WEB2086-treated (B) mice 72 h after laser treatment. Green fluorescence from isolectin B4 indicates CNV, and red fluorescence indicates F4/80-positive macrophages. The area of F4/80-positive cells was quantified and normalized to the area of CNV (C). **P<0.001 compared with vehicle-treated mice. Error bars indicate mean ± SD; vehicle, n = 16, WEB2086, n = 16. Experiments were conducted in triplicate with similar results. Scale bars in A and B are 200 μm.

doi:10.1371/journal.pone.0068173.g003
WEB2086 easily crosses vessel walls and the mucosa of the airways [41], and we speculate that it readily penetrates the retina because of its small molecular weight (456 Da). Further study is necessary to investigate the penetration, intraocular pharmacokinetics, toxicology, and the effects on retinal ultrastructure and function with intravitreal administration of WEB2086. Our results suggest that PAF-R blockage may be a useful strategy in CNV treatment.

Macrophage accumulation in the CNV area and the expression of angiogenic cytokines, such as VEGF, are involved in CNV formation [42–44]. Mice subjected to pharmacological deletion of macrophages exhibited suppressed CNV and reduced VEGF, suggesting a role for macrophages as producers and regulators of angiogenic factors in CNV pathogenesis [45,46]. In the present study, a PAF-R blockade suppressed macrophage infiltration as well as CNV development. Data of our present study are compatible with those of a recent study that observed an inhibition of macrophage infiltration and inflammatory processes following treatment with a PAF-R antagonist or in PAF-R-deficient animal in a model of renal inflammatory injury [47]. These data add to growing evidence supporting the role of chronic inflammatory processes in CNV and suggest that more research is needed to explore the therapeutic potential of anti-inflammatory therapy, such as PAF-R blockage, in AMD.

In addition to VEGF, many other angiogenic and inflammatory mediators contribute to CNV either directly via activation of their cognate receptors or indirectly via crosstalk with VEGF and other signaling pathways [48]. MCP-1, a CC chemokine ligand 1 protein, plays an important role in macrophage recruitment and is a key factor in CNV formation following laser injury. Decreased MCP-1 expression is associated with significant inhibition of macrophage infiltration and reduced CNV [49,50]; these features also are observed in CCR2-deficient mice that lack the receptor for MCP-1 [43,51]. IL-6 is a potent proinflammatory cytokine that may function in the pathogenesis of ocular neovascularization, such as proliferative diabetic retinopathy [52]. In experimental CNV, IL-6 expression is upregulated in the RPE-choroid complex, and antibody-based blockage of the IL-6 receptor or genetic ablation of IL-6 significantly suppress CNV [49]. We report that a PAF-R blockade significantly suppressed CNV-related molecules including VEGF, MCP-1, and IL-6. The suppression of VEGF and inflammation-related molecules associated with PAF-R blockage is consistent with the results of other studies that implicated PAF/PAF-R signaling in angiogenesis and inflammatory processes [53–55]. The molecular mechanisms functioning in CNV suppression by PAF-R blockage likely involve the inhibition of multiple inflammatory steps.

It is known that CNV lesions commonly evolve into scars over time as a consequence of the wound healing process. In addition, subretinal fibrosis contributes to a loss in visual acuity in neovascular AMD. A recent study documented the development or progression of submacular fibrosis following anti-VEGF therapy in patients with exudative AMD [56]. In these cases, the vascular component of AMD was treatable with anti-VEGF agents, but the visual outcome was ultimately limited by submacular fibrosis. Greater fibrotic responses after anti-VEGF therapy may result from an imbalance in the complex interactions between angiogenesis and tissue fibrosis during the wound healing process [56]. Ultimately, it is the scarring response that irreversibly damages photoreceptors; therefore, therapies that modify this response may help preserve or even rescue photoreceptors. PAF/PAF-R signaling may be a potential therapeutic target as it is believed to play a critical role in various fibrotic processes. For example, PAF signaling upregulates fibronectin expression and matrix production in tubulolipoidal cells and interstitial fibroblasts, two key cell types associated with renal fibrosis [57]. PAF-R is upregulated in experimental lung and liver fibrosis models, and PAF-R antagonists attenuate fibrotic responses [58–60]. These findings are consistent with our results, suggesting that WEB2086 substantially reduces subretinal fibrosis in a mouse model. As RPE cells, expressing PAF-R, have been identified not only as the

Figure 4. Inhibitory effects of WEB2086 on the expression of proangiogenic and proinflammatory molecules in the RPE–choroid complex. The choroidal mRNA and protein expression levels of VEGF (A, D), MCP-1 (B, E), and IL-6 (C, F) were analyzed by qRT-PCR (A–C) and ELISA (D–F) at various time points after photocoagulation. WEB2086-induced PAF-R blockage significantly suppressed the expression of these molecules, which was upregulated in the vehicle-treated mice during CNV development. *p<0.01 compared with vehicle-treated mice, *p<0.01 compared with the 0-hour baseline. Error bars indicate mean ± SD; vehicle, n = 8 for each molecule each time point, WEB2086, n = 8 for each molecule each time point. Experiments were conducted in triplicate with similar results. doi:10.1371/journal.pone.0068173.g004
central cell type in various ocular wound healing processes but also an important source of transforming growth factor-β, a key molecule, under pathologic conditions [2,61], we hypothesize that they are involved in PAF-R blockage-induced fibrosis suppression in the animal model.

In summary, the present study is the first to demonstrate that PAF-R blockage reduces CNV and subretinal fibrosis in vivo. As optimal treatment modalities for neovascular AMD would target the multiple mechanisms of AMD-associated vision loss, including neovascularization, inflammation, and fibrosis, our results support PAF-R as an attractive target in the treatment of AMD, as well as other ocular wound healing processes, such as proliferative diabetic retinopathy and retinopathy of prematurity.

**Acknowledgments**

We sincerely thank Ms. Michiyo Takahara for her excellent technical support throughout the experiments. We also thank Ms. Mari Imamura for her help in preparing the histological sections.
Conceived and designed the experiments: HZH KHS TI. Performed the experiments: HZH AT YY TY YO. Analyzed the data: HZH. Contributed reagents/materials/analysis tools: TI AT TY. Wrote the paper: HZH AT KHS.

References
1. Fine SL, Berger JW, Maguire MG, Ho AC (2000) Age-related macular degeneration. N Engl J Med 342: 483–492.
2. Fricke AJ, Crane PC, Heier JS, Boyer DS, Kaiser PK, et al. (2006) Aqueous humor levels of cytokines are related to vitreous levels and progression of wet age-related macular degeneration. Invest Ophthalmol Vis Sci 47: 3065–3072.

25. Zhang H, Sonoda KH, Hijioka K, Qiao H, Oshima Y, et al. (2009) Platelet-activating factor receptor gene expression and signal transduction. Biochem Biophys Acta 1791: 957–965.
26. Honda Z, Ichii S, Shimizu T (2002) Platelet-activating factor receptor. J Biochem 131: 773–779.
27. Ma X, Ottino P, Bazan HE, Bazan NG (2004) Platelet-activating factor (PAF) enhances vascular endothelial growth factor-induced endothelial cell motility and neangiogenesis in a murine model eye. Arterioscler Thromb Vasc Biol 24: 80–88.
28. Ko HM, Seo KH, Han SJ, Ahn KY, Choi IH, et al. (2002) Nuclear factor kappaB-dependency of platelet-activating factor-induced angiogenesis. Cancer Res 62: 1809–1814.
29. Cohen RA, Gebhardt BM, Bazan NG (1994) A platelet-activating factor antagonist reduces corneal allograft immunogenecity and neovascularization. Curr Eye Res 13: 139–141.
30. Montrucchio G, Lupia E, Battaglia E, Passerini G, Bussolati B, et al. (1998) Platelet-activating factor receptor (PAF-R) and CNV.
of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol 243: 3–8.

53. Kim HA, Seo KH, Kang YR, Ko HM, Kim KJ, et al. (2011) Mechanisms of platelet-activating factor-induced enhancement of VEGF expression. Cell Physiol Biochem 27: 53–62.

54. Ogata M, Nandate K, Kawasaki T, Kawasaki C, Ozaki M, et al. (2004) A platelet activating factor receptor antagonist inhibits cytokine production in human whole blood by bacterial toxins and live bacteria. Anesth Analg 90: 1767–1772.

55. Proudfoot JM, Croft KD, Puddey IB, Beilin LJ (2003) Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemotactic protein-1. J Pharmacol Exp Ther 305: 846–853.

56. Hwang JC, Del Priore LV, Freund KB, Chang S, Iranmanesh R. (2011) Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 42: 6–11.

57. Ruiz-Ortega M, Bustos C, Plaza JJ, Egido J. (1998) Overexpression of extracellular matrix proteins in renal tubulointerstitial cells by platelet-activating-factor stimulation. Nephrol Dial Transplant 13: 886–892.

58. Giri SN, Sharma AK, Hyde DM, Wild JS (1995) Amelioration of bleomycin-induced lung fibrosis by treatment with the platelet activating factor receptor antagonist WEB 2086 in hamsters. Exp Lung Res 21: 207–217.

59. Chen J, Ziboh V, Giri SN (1997) Up-regulation of platelet-activating factor receptors in lung and alveolar macrophages in the bleomycin-hamster model of pulmonary fibrosis. J Pharmacol Exp Ther 280: 1219–1227.

60. Yang Y, Nemoto EM, Harvey SA, Subbotin VM, Gandhi CR (2004) Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis. Gut 53: 817–823.

61. Holtkamp GM, Kijlstra A, Peek R, de Vos AF (2001) Retinal pigment epithelium-immune system interactions: cytokine production and cytokine-induced changes. Prog Retin Eye Res 20: 29–48.